Audentes Therapeutics audentestx.com


Public list: BIO 2016 (619) Pharma Startups (4733)

Audentes is a biotechnology company committed to the development and commercialization of new treatments for people with serious, rare diseases through the application of AAV gene therapy technology. The company has three products in development, AT001 for the treatment of X-Linked Myotubular Myopathy (XLMTM), AT002 for the treatment of Pompe disease, and AT003 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).

Audentes is a biotechnology company committed to the development and commercialization of new treatments for people with serious, rare diseases through the application of AAV gene therapy technology. The company has three products in development, AT0...Show all

Company (IPO / Went public)

Phone: 415-818-1001

Fax:

600 California Street
17th Floor
San Francisco, 94108
California, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Audentes Therapeutics $212.5M Jul 20, 2016
Calimmune $21.3M Aug 28, 2017
Applied Genetic Technologies $153.2M Mar 27, 2014
See all 14 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Audentes Therapeutics Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 13 investors

Competitors

Company Status Description Investors
See all 14 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)